Dr. Dustin Wilson

Assistant Professor
Pharmacy Practice
College of Pharmacy & Health Sciences
Office Address:
Maddox Hall
Mailing Address:
PO Box 1090
Buies Creek, NC 27506

Biography

Dustin Wilson, PharmD, BCPS joined the CPHS in August 2009. Dr. Wilson completed a PGY-1 Pharmacy Practice Residency at Duke University Hospital and a PGY-2 Internal Medicine/Infectious Diseases/Academics Residency with Campbell University and Duke University Hospital. He currently maintains an active clinical practice in Internal Medicine at Duke University Hospital and serves as an Internal Medicine preceptor for APPE student rotations. In addition to his teaching and clinical service, Dr. Wilson sits on various committees at the CPHS, Duke University Hospital, and the North Carolina Association of Pharmacists. Dr. Wilson’s research interests include preceptor development and infectious diseases.


Education

  • B.S., Health Sciences, East Tennessee State University
  • Pharm.D., Campbell University
  • R.Ph., NC
  • Board Certified Pharmacotherapy Specialist

Awards, Recognition & Honors

  • Professor of the Year - Class of 2013
  • Professor of the Year - Class of 2012
  • Faculty Preceptor of the Year Eastern Region - Class of 2010

Organizations

  • North Carolina Association of Pharmacists - member
  • American Society of Health-System Pharmacists - member
  • American Association of Colleges of Pharmacy - member

Editorial

  • Wilson DT, DiMondi VP, Johnson SW, Jones TM, Drew RH. Role of Isavuconazole in the Treatment of Invasive Fungal Infections. Ther Clin Risk Manag 2016, 12:1-10.
  • Jones TM, Johnson SW, DiMondi VP, Wilson DT. Focus on JNJ-Q2, a Novel Fluoroquinolone, for the Management of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections. Infect Drug Resist 2016, 9:119-128.
  • Allen D, Wilson D, Drew R, Perfect J. Azole Antifungals: 35 Years of Invasive Fungal Infection Management. Expert Rev Anti Infect Ther 2015, 13(6):787-798.
  • Wilson DT, May DB. Potential role of fosfomycin in the treatment of community–acquired lower urinary tract infections caused by extended-spectrum beta-lactamase-producing E. coli. Am J Ther 2011, July 15.